Protein PARK2 PDB

US-based Adamas Pharmaceuticals has started a pivotal Phase III clinical trial of its most advanced wholly owned product candidate ADS-5102 (amantadine HCl) for the treatment of patients with Parkinson’s disease (PD) who have developed movement disorder levodopa-induced dyskinesia (LID).

LID is a condition characterised by involuntary movements without purpose that can become severely disabling, rendering individuals with PD unable to perform routine daily tasks.

A total of 130 patients will be enrolled in the 26-week multi-centre, randomised, double-blind, placebo-controlled trial.

The Phase III trial (EASE LID) will assess the efficacy of a once-daily 340mg dose of ADS-5102 administered at bedtime for the treatment of LID in individuals with PD.

The trial’s primary endpoint is a reduction in LID as evaluated by changes in the unified dyskinesia rating scale (UDysRS), along with supporting data from secondary endpoints.

ADS-5102 is a high dose, controlled-release version of amantadine, that is administered once-daily at bedtime.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"LID frequently occurs in patients after long-term treatment with levodopa, the most widely used drug for PD."

LID frequently occurs in patients after long-term treatment with levodopa, the most widely used drug for PD.

At present, there are no approved drugs for the treatment of LID in the US or Europe.

The company is also assessing ADS-5102 as a potential treatment for chronic behavioural symptoms associated with traumatic brain injury (TBI).

Parkinson’s disease causes tremors, rigidity, slowed movements and postural instability, and the most commonly prescribed treatments for this disorder are levodopa-based therapies.

Adamas’ portfolio also includes a fixed-dose combination product candidate, MDX-8704, being developed with Forest Laboratories and an approved controlled-release product Namenda XR, which Forest developed and is marketing in the US under an exclusive licence from Adamas.

Image: PDB rendering of Parkin (ligase). Photo: courtesy of Emw.